1[1]Houston D,Vanhoulc P.Serotonin and the vascular systerm:Role in heath and discase and implications for therapy[J].Drugs,1986:31,149-163.
2[2]Furness JB,Costa M.Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system:their projection in the guinea pig small intestine[J].Neuroscience,1982,7(2):341-349.
3[3]Saxena PR.Historical aspects of 5-HT discovery and receptor classification.In:5-HTmachanisms in primary headache[J].New York:Ranew Press,1992:3-18.
4[4]American Diabetes Association Screening for type 2 diabetes[J].Diabetes Care,2000,23(suppl):S20-s23.
5[5]Nakamura K,Kariyazono H,Masuda H,et al.Effects of sarpogrelate hydrochloride on adenosine diphosphate-or collagen-induced platelet responses in arteriosclerosis obliterans[J].Blood Coagul Fibrinolysis.2001 Jul;12(5):391-397.
6[6]Wiernsperger NF.Serotonin,5-HT2 receptors,and their blockade by naftidrofuryl:a targeted therapy of vascular diseases[J].J Cardiovasc Pharmacol.1994;23 Suppl 3:S37-43.
7[7]Raskin P.Risk factors for the development of diabetic complications[J].J Diabetes Complications.1994 Oct-Dec;8(4):195-200.
8[8]Goppelt-Struebe M,Wiedemann T,Heusinger-Ribeiro J,et al.Cox-2 and osteopontin in cocultured platelets and mesangial cells:role of glucocorticoids[J].Kidney Int.2000 Jun;57(6):2229-2238.
9[9]Young BA,Johnson RJ,Alpers CE,et al.Cellular events in the evolution of experimental diabetic nephropathy[J].Kidney Int.1995 Mar; 47(3):935-944.
